Parkinson's Disease Market Report 2026

Parkinson's Disease Market Overview

• Parkinson's Disease market size has reached to $3.62 billion in 2025 • Expected to grow to $5.32 billion in 2030 at a compound annual growth rate (CAGR) of 8% • Growth Driver: Impact Of Increasing Neurodegenerative Diseases On The Growth Of The Market • Market Trend: Advancements In Parkinson’s Disease Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Parkinson's Disease Market?

Parkinson's disease is a progressive neurological disorder that affects movement due to the loss of dopamine-producing brain cells. It primarily causes tremors, muscle stiffness, slowed movement, and balance difficulties. Treatment often involves medications such as levodopa to alleviate symptoms, complemented by physical therapy and, in certain cases, surgical interventions such as deep brain stimulation. The main drug classes used in the treatment of parkinson's disease include dopamine agonists, catechol-O-methyltransferase inhibitors, monoamine oxidase B inhibitors, anticholinergics, carbidopa-levodopa, and others. Dopamine agonists are medications that mimic the effects of dopamine in the brain, helping to manage the symptoms of the disease. The route of administration for these drugs includes oral, injectable, intestinal infusion, subcutaneous, and other methods, depending on the specific treatment needs. Distribution channels for Parkinson's disease medications include retail pharmacies, hospital pharmacies, and online pharmacies, ensuring broad accessibility. Patient care settings for those receiving parkinson's disease treatment are primarily clinics and hospitals, where healthcare professionals can closely monitor and manage the condition.

What Is The Parkinson's Disease Market Growth Forecast?

The parkinson's disease market size is expected to see strong growth in the next few years. It will grow to $5.32 billion in 2030 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to development of novel dopamine and non-dopamine therapies, increasing prevalence of aging population, rising adoption of deep brain stimulation procedures, growing focus on personalized medicine approaches, expansion of neurology specialty clinics. Major trends in the forecast period include rising adoption of combination drug therapies, increasing use of deep brain stimulation procedures, growth of early-stage diagnosis and intervention, expansion of multidisciplinary parkinson’s care programs, improved symptom management through personalized treatment plans.

Global Parkinson's Disease Market Segmentation

1) By Drug Class: Dopamine Agonists, Catechol-O-Methyltransferase Inhibitors, Monoamine Oxidase B Inhibitors, Anticholinergics, Carbidopa-Levodopa, Other Drug Classes 2) By Route Of Administration: Oral, Injectable, Intestinal infusion, Subcutaneous, Other Routes Of Administrations 3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies 4) By Patient Care Setting: Clinics, Hospitals Subsegments: 1) By Dopamine Agonists: Ergot Derivatives, Non-Ergot Derivatives 2) By Catechol-O-Methyltransferase (COMT) Inhibitors: Entacapone, Tolcapone, Opicapone 3) By Monoamine Oxidase B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide 4) By Anticholinergics: Trihexyphenidyl, Benztropine, Procyclidine 5) By Carbidopa-Levodopa: Immediate-Release Formulation, Extended-Release Formulation, Inhaled And Intestinal Gel Formulations 6) By Other Drug Classes: Amantadine And Derivatives, Adenosine A2A Receptor Antagonists, Glutamate Antagonists

What Is The Driver Of The Parkinson's Disease Market?

Increasing prevalence of neurodegenerative diseases is expected to propel the growth of the parkinson's disease market going forward. Neurodegenerative diseases refer to a group of disorders characterized by the progressive degeneration and loss of function of neurons in the brain and nervous system. The prevalence of neurodegenerative diseases is increasing due to factors such as an aging population, genetic predisposition, environmental influences, improved diagnosis, rising chronic health conditions, and lifestyle changes. Parkinson's disease helps advance the understanding of neurodegenerative diseases by providing critical insights into their underlying mechanisms, potential therapeutic targets, and the development of innovative treatment approaches. For instance, in 2025, according to the National Institutes of Health (NIH), a US-based government’s primary medical research agency, the projected prevalence of Parkinson’s disease for 2050 is estimated at 267 cases per 100,000 people, with a range of 230 to 320. Therefore, the increasing prevalence of neurodegenerative diseases is driving the growth of the parkinson's disease industry.

Key Players In The Global Parkinson's Disease Market

Major companies operating in the parkinson's disease market are Roche Holding AG, AbbVie Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, UCB S.A., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Amneal Pharmaceuticals Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Intracellular Therapies Inc., Voyager Therapeutics Inc., Sage Therapeutics Inc., Adamas Pharmaceuticals Inc., Sun Pharma Advanced Research Company Ltd., Neuraly Inc., Mitsubishi Tanabe Pharma Corporation, Athira Pharma Inc., VistaGen Therapeutics Inc.

Global Parkinson's Disease Market Trends and Insights

Major companies operating in the parkinson’s disease market are focusing on developing innovative solutions, such as levodopa-based therapy, to improve motor function and provide continuous symptom management for patients with advanced parkinson’s disease. Levodopa-based therapy involves using levodopa, a medication that converts into dopamine in the brain, to enhance motor function and alleviate symptoms of Parkinson's disease. For instance, in October 2024, AbbVie Inc., a US-based biopharmaceutical company, received US Food and Drug Administration (FDA) approval for VYALEV, a combination therapy containing levodopa and carbidopa, created for the treatment of Parkinson's disease. Its formulation aims to improve the efficacy of levodopa by inhibiting its breakdown before reaching the brain, thereby increasing dopamine levels. This medication is effective in managing motor symptoms of Parkinson's disease, including tremors, rigidity, and bradykinesia, which in turn enhances the patient's ability to carry out daily tasks. It is recognized as a key therapeutic solution for patients with Parkinson's disease experiencing motor fluctuations.

What Are Latest Mergers And Acquisitions In The Parkinson's Disease Market?

In August 2024, AbbVie Inc., a US-based pharmaceutical company, acquired Cerevel Therapeutics Holdings Inc. for an undisclosed amount. With this acquisition, AbbVie enhanced its neuroscience portfolio and addressed unmet medical needs in psychiatric and neurological disorders. Cerevel Therapeutics Holdings, Inc., is a US-based biotechnology company that focuses on developing treatments for Parkinson's disease.

Regional Outlook

North America was the largest region in the parkinson's disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the parkinson's disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the parkinson's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Parkinson's Disease Market?

The parkinson's disease market consists of revenues earned by entities providing services such as speech therapy, and physical therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The parkinson's disease market also includes sales of amantadine and adenosine A2A receptor antagonists. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Parkinson's Disease Market Report 2026?

The parkinson's disease market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the parkinson's disease industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.